• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Vaia Florou, MD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
50 4.9 out of 5 Patient Rating

Languages Spoken: English, Modern Greek (1453-)

Vaia Florou is an Assistant Professor in the Division of Oncology at Huntsman Cancer Institute of the University of Utah in Salt Lake City, Utah. Her clinical and research interests are focused on sarcomas and gastrointestinal malignancies, with an emphasis on immunotherapy and targeted therapies. Dr. Florou received her medical degree from the University of Patras in Patras, Greece. Prior to her clinical training, she was a research fellow at the University of Cologne in Germany, where she studied the B-cell receptor signaling in CLL. She then completed her Internal Medicine Residency at Rutgers Robert Wood Johnson/Saint Peter’s University Hospital in New Brunswick, New Jersey with an additional year as Chief Medical Resident. She pursued a Hematology and Oncology fellowship at the University of Miami in Miami, Florida where she graduated from in 2019.

She is involved in clinical trials aiming to improve immunotherapy efficacy in sarcomas and gastrointestinal malignancies. Her research has been presented at various national and international conferences including ASCO, AACR, SITC, ISTH and CTOS. She is also a member of several professional organizations like the American Society of Clinical Oncology, European Society for Medical Oncology, Connective Tissue Oncology Society and Society for Immunotherapy of Cancer.

Specialties

  • Gastrointestinal Malignancies
  • Medical Oncology
  • Sarcomas

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor (Clinical)
Academic Divisions Oncology
Board Certification American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.9/ 5

Care provider's explanation of condition/problem

4.9/ 5

Care provider's effort to include me in decisions

4.9/ 5

Wait time at clinic

4.7/ 5

Care provider's concern for questions & worries

4.9/ 5

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient October 30, 2022
Huntsman Cancer Institute

5 out of 5 stars

The doctor is great!

UofU Patient October 30, 2022
Huntsman Cancer Institute

5 out of 5 stars

I was impressed with Dr Florou's professionalism, knowledge and patience. She took the time to answer all my questions.

UofU Patient October 21, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Florou and Dr Decesaris have both been fantastic during all of my visits.

UofU Patient October 10, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very professional and kindest

UofU Patient September 26, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient September 19, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. Foreau is great

UofU Patient September 16, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. Florou is a wonderful person, right to the point. She has made me feel very comfortable. I am so glad she is treating me in Oncology.

UofU Patient September 12, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very professional, polite, practical language for understanding the patient situation

UofU Patient September 06, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

My doctor was informative and patient with my questions.

UofU Patient September 02, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Florou is an excellent Doctor

UofU Patient August 28, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

The doctor is a wonderful person, politely and respectful,

UofU Patient August 21, 2022
HUNTSMAN CANCER CENTER

4 out of 5 stars

Care provider is a straight shooter with information

UofU Patient August 15, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient August 13, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very good

UofU Patient August 02, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient July 23, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient July 20, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. Florou had reviewed my history thoroughly and had an amazing recall of my on-going (8 year) challenge with cancer. I look forward to a good working relationship with her and Breanna.

UofU Patient July 19, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient June 27, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient June 05, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient May 23, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient May 22, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Florou changed every aspect of my treatment and understanding of my cancer. We tell everyone we know how different the care is at Huntsman. We have great hospitals closer to our home, but she guided us to the right surgeon and speeded up the process.

UofU Patient May 09, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient April 28, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

With the technology, I could only see the top of Dr. Florou's head.

UofU Patient April 19, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Florou is always good to explain any care decisions and options. I struggle to make decisions sometimes and I am glad she can do that for me when I can't decide what is best. She is kind and caring always to me

UofU Patient April 17, 2022
HUNTSMAN CANCER CENTER

1 out of 5 stars

Feel like my concerns wasn't heard

UofU Patient March 29, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient March 14, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient March 10, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

Vaia Florou is an Assistant Professor in the Division of Oncology at Huntsman Cancer Institute of the University of Utah in Salt Lake City, Utah. Her clinical and research interests are focused on sarcomas and gastrointestinal malignancies, with an emphasis on immunotherapy and targeted therapies. Dr. Florou received her medical degree from the University of Patras in Patras, Greece. Prior to her clinical training, she was a research fellow at the University of Cologne in Germany, where she studied the B-cell receptor signaling in CLL. She then completed her Internal Medicine Residency at Rutgers Robert Wood Johnson/Saint Peter’s University Hospital in New Brunswick, New Jersey with an additional year as Chief Medical Resident. She pursued a Hematology and Oncology fellowship at the University of Miami in Miami, Florida where she graduated from in 2019.

She is involved in clinical trials aiming to improve immunotherapy efficacy in sarcomas and gastrointestinal malignancies. Her research has been presented at various national and international conferences including ASCO, AACR, SITC, ISTH and CTOS. She is also a member of several professional organizations like the American Society of Clinical Oncology, European Society for Medical Oncology, Connective Tissue Oncology Society and Society for Immunotherapy of Cancer.

Academic Locations

Huntsman Cancer Institute Research South

801-585-0255

2000 Circle of Hope
Suite 2100
Salt Lake City, UT  84112

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor (Clinical)
Academic Divisions Oncology
Board Certification American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)

Education History

Graduate Training University of Utah
Biomedical Informatics
M.S., 2022
Fellowship Jackson Memorial Hospital/University of Miami
Hematology/Oncology
Clinical Fellow, 2019
Chief Resident Rutgers Robert Wood Johnson Medical School/Saint Peter’s University Hospital
Internal Medicine
Chief Resident, 2016
Residency Rutgers Robert Wood Johnson Medical School/Saint Peter’s University Hospital
Internal Medicine
Resident, 2015
Graduate Training Rutgers University/Saint Peter’s University Hospital
Strategic Healthcare Management Program
Mini-M.B.A., 2013
Research Fellow University of Cologne, Faculty of Medicine
Hematology/Oncology
Research Fellow, 2012
Professional Medical University of Patras, Faculty of Medicine
Medicine
M.D., 2010

Selected Publications - Journal Articles

Journal Article

  1. Florou V, Wilky BA (2022). Emerging mechanisms of immunotherapy resistance in sarcomas. . Cancer Drug Resist, (10.20517).
  2. Kourouni I, Aesif SW, Tamarkin SW, Bolen M, Sivak E, Shaman Z, Tamaskar I, Florou V (2021). A 51-year-old man with chronic cough and left hilar prominence. Breathe (Sheff), 17(2), 210018.
  3. Florou V, Jarboe E, Deftereos G (2020). Intravenous Leiomyomatosis: A Rare Diagnosis With Aggressive Potential. JCO Oncol Pract, 17(4), 206-208.
  4. Naqash AR, Ricciuti B, Owen DH, Florou V et al (2020). Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother, s00262-020-02536-5(10.1007), 1177-1187.
  5. Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR (2020). Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother, 69(7), 1177-1187.
  6. Florou V, Garrido-Laguna I (2020). Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward? J Immunother Precis Oncol 3 (3), 137-139. J Immunother Precis Oncol, 137-139.
  7. Florou V, Trent JC, Wilky BA (2019). Precision medicine in gastrointestinal stromal tumors. Discov Med, (155), 267-276.
  8. Florou V, Garrido-Laguna I (2019). Cancer immunotherapy in the immunosuppressed patients and its relevance to clinical practice. J Immunother Precis Oncol 2:127. J Immunother Precis Oncol.
  9. Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W (2019). Clinical and immunological implications of frameshift mutations in lung cancer. J Thorac Oncol, (10.1016).
  10. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC (2019). Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol, (10.1016), 30153-6.
  11. Florou V, Ramdial JL, Trent JC (2018). Use of Tyrosine Kinase Inhibitors in Patients With GI Stromal Tumor Who Are Pregnant or Considering Pregnancy: Driver Mutations and Circulating Tumor DNA. J Clin Oncol, 36(25), 2659-60.
  12. Florou V, Ramdial J, Trent JC (2017). GIST in Pregnancy: The Role of Circulating Tumor DNA to Define the Assessment of Risk of Rapid Progression and Response to Imatinib. Am J Hematol Oncol, 13(11), 37-40.
  13. Florou V, Rosenberg AE, Wieder E, Komanduri K V, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA (). Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. (Epub ahead of print) J Immunother Cancer.

Review

  1. Mittra A, Takebe N, Florou V, Chen AP, Naqash AR (2020). The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. [Review]. Hum Vaccin Immunother, 17(7), 1935-1939.
  2. Florou V, Wilky BA (2021). Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. [Review]. Curr Treat Options Oncol, 22(7), 61.
  3. Florou V, Puri S, Garrido-Laguna I, Wilky BA (2020). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. [Review]. Ann Transl Med, 9(12), 1035.
  4. Bindal P, Gray JE, Boyle TA, Florou V, Puri S (2020). Biomarkers of therapeutic response with immune checkpoint inhibitors. [Review]. Ann Transl Med, 9(12), 1040.
  5. Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodriguez-Ruiz ME, Sheffer M, Church S, Fuhrman C, Overacre-Delgoffe A, Nguyen R, Florou V, Thaxton JE, Aggen DH, Guerriero JL (2021). Considerations for treatment duration in responders to immune checkpoint inhibitors. [Review]. J Immunother Cancer, 9(3).
  6. Florou V, Trent JC, Wilky BA (2020). Precision medicine in gastrointestinal stromal tumors. [Review]. Discov Med, 28(155), 267-276.
  7. Florou V, Wilky BA (2018 Mar 8). Current and Future Directions for Angiosarcoma Therapy. [Review]. Curr Treat Options Oncol, 19(3), 14.
  8. Alavi SN, Florou V, Tinoco G, Trent JC, Wilky BA (2018). A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib. [Review]. Discov Med, 25(137), 131-44.
  9. Florou V, Wilky BA, Trent JC (2017). Latest advances in adult gastrointestinal stromal tumors. [Review]. Future Oncol, 13(24), 2183-93.
  10. Warner K, Crispatzu G, Al-Ghaili N, Weit N, Florou V, You MJ, Newrzela S, Herling M (2013). Models for mature T-cell lymphomas--a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts. [Review]. Crit Rev Oncol Hematol, 88(3), 680-95.

Book Chapter

  1. Florou V, Wilky BA (2018). Regulatory T Cells. In D'Angelo S, Pollack S (Eds.), Immunotherapy of Sarcoma (pp. 33-45). Springer.
  2. Florou V, Nascimento AG, Gulia A, de Lima Lopes Jr G (2018). Global Health Perspective in Sarcomas and Other Rare Cancers. In American Society of Clinical Oncology, Educational Book (38, pp. 916-24).
  3. Florou V, Wilky BA, Rosenblatt JD, Zhang Y (In Press). B cells in the Tumor Microenvironment. In Cancer Immunotherapy Principles and Practice. McGraw-Hill.

Case Report

  1. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482.
  2. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4.
  3. Cioffi JH, Estes DJ, Florou V, Ardalan B (2017). Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.LID - bcr-2017-220952 [pii]LID - 10.1136/bcr-2017-220952 [doi]. BMJ Case Rep, 2017.

Abstract

  1. Florou V, Wilky B, Trent J (2019). Angiosarcoma treated with checkpoint inhibitors: A single-institution experience. Abstract. ASCO 2019 [Abstract].
  2. Florou V, Park W, Torres A, Algaze S, Saravia D, Kwon D, Hosein P, Merchan J, Wilky B, Lockhart C, Lopes G (2018). High Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) and its Reactive Increase as Better Predictors of Poor Clinical Outcomes Compared To Tumor Mutation Burden (TMB), in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors [Abstract]. J Clin Oncol, 36(no. 18_suppl), abstr e24109.
  3. Espejo A, Florou V, Subhawong T, Trent JC (2018). Safety and efficacy of olaratumab added to doxorubicin- based combination chemotherapy in the treatment of advanced soft-tissue sarcoma (STS) [Abstract]. J Clin Oncol, 36(no. 18_suppl), abstr e23542.

Global Impact

Education History

Research Fellow University of Cologne, Faculty of Medicine
Hematology/Oncology
Research Fellow
Professional Medical University of Patras, Faculty of Medicine
Medicine
M.D.

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Price Estimate
  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

Appointment Scheduling:
801-213-9500

Hospital Operator:
801-581-2121

En Español:
801-646-5914

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2023 University of Utah Health